Clinical trial · Observational
Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No funding
Summary
Brief summary (as posted)
Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia | ONTOLOGY_EXACT | 0.98 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- A
- description
- Non anticoagulant and/or antiplatelet users.
- label
- B
- description
- Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
- label
- C
- description
- Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
Primary outcomes (8)
- measure
- Perioperative blood transfusion
- timeFrame
- in 1 week after surgery
- measure
- Bladder clots
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Admitted to National Cheng Kung University Hospital Urology during the study * Older than 20 years old * Agree to participate this study * Receiving transurethral resection of the prostate for benign prostatic hyperplasia or prostate cancer Exclusion Criteria: * Poor expression ability and without close care givers to answer questions
References
Publications (0)
Data not yet available